Fischer et al. Lower-Risk Cannabis Use Guidelines: A Comprehensive Update of Evidence and Recommendations. American Journal of Public Health, 2017; e1. dx.doi.org/10.2105/AJPH.2017.303818.
Wettlaufer et al. Estimating the harms and costs of cannabis-attributable collisions in the Canadian provinces. Drug and Alcohol Dependence; 2017;173:185-190. dx.doi.org/10.1016/j.drugalcdep.2016.12.024
Devinsky et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. N Engl J Med; 2017;376:2011-2020. dx.doi.org/10.1056/NEJMoa1611618
West, JC. Medical marijuana: Challenges and risk issues for health care providers. J of Healthcare Risk Mgmt; 2017;36:38-43. dx.doi.org/10.1002/jhrm.21267
Hazekamp A, Heerdink, ER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol; 2013 Aug;69(8):1575-80. ncbi.nlm.nih.gov/pubmed/23588562
Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids--an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013 Jul-Aug;45(3):199-210. ncbi.nlm.nih.gov/pubmed/24175484
Kahan M, Srivastava A, Spithoff S, Bromley L. Prescribing smoked cannabis for chronic noncancer pain: preliminary recommendations. Can Fam Physician. 2014 Dec; 60(12):1083-90. ncbi.nlm.nih.gov/pmc/articles/PMC4264803/
Lucas, P. Cannabis as an Adjunct to or Substitute for Opiates in the Treatment of Chronic Pain, Journal of Psychoactive Drugs, 2012, 44:2, 125-133. doi:10.1080/02791072.2012.684624
Lucas et al. Cannabis as a substitute for alcohol and other drugs: A dispensary-based survey of substitution effect in Canadian medical cannabis patients. Addiction Research and Theory, 2013, 21(5): 435–442. dx.doi.org/10.3109/16066359.2012.733465
Lucas et al. Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients: The impact of contextual factors. Drug and Alcohol Review, 2015. ncbi.nlm.nih.gov/pubmed/26364922.
Lucas, P., Walsh, Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. International Journal of Drug Policy, 2017, 42, 30–35. ncbi.nlm.nih.gov/pubmed/28189912
Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015 Jun 23;313(24):2456-73. jamanetwork.com/journals/jama/fullarticle/2338251
Tsang CC, Giudice MG. Nabilone for the management of pain. Pharmacotherapy. 2016 Mar; 36(3):273-86. ncbi.nlm.nih.gov/pubmed/26923810
Deshpande A, Mailis-Gagnon A, Zoheiry N, Lakha SF. Efficacy and adverse effects of medical marijuana for chronic noncancer pain: systematic review of randomized controlled trials. Can Fam Phys; 2015 Aug;61(8):e372-81. ncbi.nlm.nih.gov/pubmed/26505059
Koppel BS, Brust JCM, Fife T, Bronstein J, Youssof S, Gronseth G, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders (Report of the Guideline Development Subcommittee of the American Academy of Neurology. 2014;82(17):1556-1563. neurology.org/content/82/17/1556.full.pdf+html
Medicinal cannabis; 2016. [The Narcotic Drugs Amendment Bill was passed by the Australian Parliament on 24 February 2016. The Narcotic Drugs Amendment Act 2016 enables a sustainable supply of safe medicinal cannabis products to Australian patients.]